Cemiplimab for kidney transplant patients with advanced skin cancer
Treatments studied
Part of Cancer, Immune system & allergy, Kidney & urinary, Skin clinical trials.
This trial tests a drug called cemiplimab (Libtayo) for kidney transplant recipients who have advanced skin cancer (cutaneous squamous cell carcinoma). The treatment aims to help your immune system fight the cancer while managing your transplant medicines to keep your kidney healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a kidney transplant at least 6 months ago, and your kidney is working well (GFR at least 30).
- You have advanced skin cancer that cannot be removed by surgery or has spread to other parts of the body.
- You are 18 years or older and able to switch to specific anti-rejection medicines (sirolimus and prednisone).
- You have not had certain prior cancer treatments like PD-1/PD-L1 inhibitors or other checkpoint blockers.
- You do not have serious heart problems, uncontrolled infections, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug (cemiplimab) injected directly into early-stage skin cancer (squamous cell carcinoma) to see if it can shrink or cure the cancer before surgery. It may help patients avoid more extensive surgery or reduce the chance of the cancer coming back.
This trial is testing whether a new blood test can predict how well the drug cemiplimab works for skin cancer and if it causes side effects. It may help doctors better match treatments to patients.
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
Hear when a new Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.